The pathophysiology observed in an array of human diseases is the result primarily of the aberrant activity of one or more enzymes. Thus, understanding the biochemical basis underlying a disease invariably paves the way toward the development of therapeutic agents capable of arresting or modulating the deleterious activity of a target enzyme. It also places the design of these agents on a sound biochemical footing. Rational drug design is a complex task involving the application of the fundamental principles of mechanistic enzymology and physical organic chemistry in the development of therapeutic agents. An integral part of this process is the use of a range of powerful tools, including x-ray crystallography, computational chemistry and computer graphics and modeling, structureactivity relationship studies, molecular biology, nuclear magnetic resonance spectroscopy, etc. (Bugg, Carson, and Montgomery, 1993). Therapeutic agents that exert their action by blocking the action of an enzyme, may consist of a single recognition component, as in competitive inhibitors, or a recognition component tethered to a reactive center (Weinbaum and Groutas, 1991). Frequently, the recognition component is a small peptide chain the selection of which is based on the known substrate specificity of the target enzyme. The reactive center may embody latent reactivity, as is the situation with mechanism-based inhibitors (Abell, 1992). Geometric and charge complementarity are two salient features common to both substrates and inhibitors. Some examples illustrating these principles are given here.
Read full abstract